Business Wire

Thales Prepares to Secure European Infrastructures Against Attacks From Future Quantum Computers

14.4.2023 15:03:00 EEST | Business Wire | Press release

Share

As a driving force in the second quantum revolution, Thales has joined forces with around twenty deep tech, academic and industry partners, as part of the EuroQCI initiative (European Quantum Communication Infrastructure), which aims to deploy a quantum communication infrastructure for EU member states within three years.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230414005211/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Carlos Castilla

By 2040, quantum computers could use their unprecedented computational power to decode encrypted data, incomparably threatening the security of even the best-protected communication systems. EuroQCI aims to counter that threat by developing sovereign systems to protect the communications and data assets of critical infrastructure providers and government institutions.

The longer-term objective of the initiative is to create a Quantum Information Network (QIN) that will harness the phenomenon of quantum entanglement not only to guarantee communications security but also to create networks of quantum sensors and processors, which have the potential to drive exponential increases in the already outstanding performance of quantum sensors and quantum computers.

As part of this effort, today, Thales is breaking new ground as a member of multiple new consortia that have been set up since late 2022 in these domains:

  • Quantum repeaters, with the Delft University: QIA (Quantum Internet Alliance) – led by the Delft University of Technology in the Netherlands – is working to demonstrate the feasibility of connecting users in two metropolitan areas 500 km apart, using quantum repeaters, which can compensate for the loss of information via a quantum memory;
  • Quantum key distribution: QKISS – coordinated by Exail – and QUARTER – led by LuxQuanta – are developing Quantum Key Distribution systems to protect users' critical communications from cyberattacks.
  • Certification of quantum communication: PETRUS – led by Deutsche Telekom – is the official coordinator of 32 EuroQCI projects, on behalf of the European Commission. It is also developing a framework for certification and accreditation of quantum communication products and networks.
  • Satellites quantum communications: TeQuantS – led by Thales Alenia Space – aims at developing quantum space-to-Earth communications technologies, necessary for cybersecurity applications and future quantum information networks, through the construction of satellites and optical ground stations by the end of 2026.

Specifically, the Thales teams taking part in these projects are working to develop quantum key generation, distribution and management equipment and the associated communication encryption devices, as well as defining the architecture of these quantum communication infrastructures.

Thales operates the largest quantum physics research facilities in Europe, in partnership with the CNRS, and some 100 engineers and researchers are currently engaged in the development of the quantum solutions (sensors, communications and algorithms) that will play a foundational role in tomorrow's world. These new consortia will all benefit from Thales's multi-disciplinary expertise, in particular in the field of secure communication networks.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Digital Identity & Security. It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Edge computing, 6G and cybersecurity.

Thales has 77,000 employees in 68 countries. In 2022, the Group generated sales of €17.6 billion.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS

Thales, Media Relations
Philomène Emptaz
philomene.emptaz@thalesgroup.com
06. 59. 06. 98. 76

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye